IDH2型
胶质瘤
IDH1
遗传学
突变体
生物
癌症研究
基因
作者
Ingo K. Mellinghoff,Martin J. van den Bent,Deborah T. Blumenthal,Mehdi Touat,Katherine B. Peters,Jennifer Clarke,Joe Mendez,Shlomit Yust‐Katz,Liam Welsh,Warren Mason,François Ducray,Yoshie Umemura,Burt Nabors,Matthias Holdhoff,Andreas F. Hottinger,Yoshiki Arakawa,Juan Manuel Sepúlveda-Sánchez,Wolfgang Wick,Riccardo Soffietti,James Perry
标识
DOI:10.1056/nejmoa2304194
摘要
In patients with grade 2 IDH-mutant glioma, vorasidenib significantly improved progression-free survival and delayed the time to the next intervention. (Funded by Servier; INDIGO ClinicalTrials.gov number, NCT04164901.).
科研通智能强力驱动
Strongly Powered by AbleSci AI